Webinar 👩💻 What’s Glycemic Control Costing You? → Register Free
Blog
Insulin: Lifesaver or Killer? Part 2
Clinical Consequences of Severe Hypoglycemia
In part 1 of this series, we described a scenario of a patient receiving intensive insulin therapy, and the most frequent critical complication to follow: hypoglycemia. Not only are there patient risks of severe hypoglycemia, there are clinical consequences as well.
The clinical effects of hypoglycemia include:
- Hospital admissions – In a prospective study of well-controlled elderly T2DM patients, 25% of hospital admissions for diabetes were for severe hypoglycemia.¹
- Increased mortality – In a study of severe sulfonylurea-associated hypoglycemia, 9% ended in a fatality.²
- Hospital Acquired Conditions – hypoglycemia is considered a manifestation of poor glycemic control and a Hospital-Acquired Condition for which the Centers for Medicare and Medicaid Services will not pay.³
- Economic consequences – In a retrospective analysis of 536,581 patients with type 2 diabetes from 2004 to 2008, hypoglycemia cost over 52 million dollars.⁴
Hospitals and caregivers should do what they can to avoid the above consequences. Stay tuned for part three of our series next week. We will explain the types of strategies that can be executed to minimize the risk of hypoglycemia.
References:
- Greco D, et al. Diab Nutr Metab. 2004,17:23-26.
- Campbell IW. Horm Metab Res Suppl. 1985,15:105-111.
- Manifestations of Poor Glycemic Control. Changes to the Hospital Inpatient Prospective Payment Systems and Fiscal Year 2009 Rates. Department of Health and Human Services, Centers for Medicare and Medicaid Services. 42 CFR Parts 411, 412, 413, 422, and 489 (19 August 2008) pp. 48433-49084.
- Quilliam BJ, et al. Am J Manag Care. 2011,17:673-680.
Related posts

News
Monarch Medical Technologies Joins Glooko to Advance Connected Diabetes Care
Monarch Medical Technologies Joins Glooko to Advance Connected Diabetes Care
We are excited to announce that Monarch Medical Technologies, the creator of EndoTool® Glucose Management System, has been acquired by Glooko, a global leader in diabetes management solutions. For EndoTool customers, nothing changes in the care and support you receive. ...

Blog
5 Tips to Build a Winning Business Case for Patient-Specific Insulin Dosing Software
5 Tips to Build a Winning Business Case for Patient-Specific Insulin Dosing Software
When clinicians ask me, "How do we move beyond standard insulin protocols and implement a glycemic management software solution without getting stuck in committee?" My answer is simple: pair clinical impact with financial clarity. Below are five practical tips I've ...

Blog
Monarch Medical Technologies Named Among TIME’s World’s Top HealthTech Companies 2025
Monarch Medical Technologies Named Among TIME’s World’s Top HealthTech Companies 2025
Innovation in patient-specific insulin dosing just earned global recognition as Monarch Medical Technologies has been recognized by TIME and Statista on their list of the World's Top HealthTech Companies 2025. This recognition underscores the impact of our mission: creating a ...
Get in Touch
Ready to get started?
Fill in your details and one of our friendly team members will be in touch to show you how easily EndoTool can support your hospital.
"*" indicates required fields